Does rosuvastatin delay progression of atherosclerosis in people with HIV infection at moderate cardiovascular risk? A randomized, multicentre placebo controlled trial

Completed

• Conditions: Cardiovascular disease; HIV; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system; Infection - Acquired immune deficiency syndrome (AIDS / HIV)

• Registration Number: ACTRN12612001082897
• Lead Sponsor: Jennifer Hoy

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-10-09
• Study Completion: 2018-07-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 85

Inclusion Criteria

Adults with proven HIV infection who are on a stable combination anti-retroviral therapy regimen with a plasma HIV viral load < 200 copies/ml for > six months AND
who are at moderate cardiovascular risk , as estimated by a Framingham Risk score of 10-15% 10 year risk of cardiovascular disease

Exclusion Criteria

- Fullfilling any current indication for lipid lowering therapy
- Any contraindication to rosuvastatin therapy (including previous allergy, pregnancy, myopathy, creatinine clearance <30ml/min)
- Use of contraindicated concurrent medications (cyclosporine, Gemfibrozil, Niacin, Fusidic acid)

Study & Design

• Study Type: Interventional
• Study Design: Not specified